Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Braz. j. med. biol. res ; 51(10): e7579, 2018. graf
Article in English | LILACS | ID: biblio-951716


Glucocorticoid insensitivity is an important barrier to the treatment of several inflammatory diseases, including acute lung injury (ALI). Saquinavir (SQV) is an inhibitor of the human immunodeficiency virus protease, and the therapeutic effects of SQV in ALI accompanied with glucocorticoid insensitivity have not been previously investigated. In this study, the effects of SQV on lipopolysaccharide (LPS)-mediated injury in human pulmonary microvascular endothelial cells (HPMECs), human type I alveolar epithelial cells (AT I), and alveolar macrophages were determined. In addition, the effects of SQV on an LPS-induced ALI model with or without methylprednisolone (MPS) were studied. In LPS-stimulated HPMECs, SQV treatment resulted in a decrease of high mobility group box 1 (HMGB1), phospho-NF-κB (p-NF-κB), and toll-like receptor 4 (TLR4), and an increase of VE-cadherin. Compared to MPS alone, MPS plus SQV attenuated the decrease of glucocorticoid receptor alpha (GRα) and IκBα in LPS-stimulated HPMECs. HMGB1, TLR4, and p-NF-κB expression were also lessened in LPS-stimulated alveolar macrophages with SQV treatment. In addition, SQV reduced the injury in human AT I with a decrease of HMGB1 and p-NF-κB, and with an increase of aquaporin 5 (AQP 5). SQV ameliorated the lung injury caused by LPS in rats with reductions in vascular permeability, myeloperoxidase activity (MPO) and histopathological scores, and with lowered HMGB1, TLR4, and p-NF-κB expression, but with enhanced VE-cadherin expression. By comparison, SQV plus MPS increased GRα and IκBα in lung tissues of rats with ALI. This study demonstrated that SQV prevented experimental ALI and improved glucocorticoid insensitivity by modulating the HMGB1/TLR4 pathway.

Animals , Male , Rats , Methylprednisolone/administration & dosage , Saquinavir/administration & dosage , Acute Lung Injury/drug therapy , Signal Transduction/drug effects , Antigens, CD/drug effects , Antigens, CD/metabolism , Cadherins/drug effects , Cadherins/metabolism , Lipopolysaccharides , Rats, Sprague-Dawley , HMGB1 Protein/drug effects , HMGB1 Protein/metabolism , Disease Models, Animal , Toll-Like Receptor 4/drug effects , Toll-Like Receptor 4/metabolism , Acute Lung Injury/chemically induced
Biol. Res ; 48: 1-8, 2015. ilus, graf, tab
Article in English | LILACS | ID: lil-734619


BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely used in clinical trials but received no encourage results. The major problem was the fate of engrafted MSCs in vivo could not be defined. Some studies indicated that MSCs could induce immune response and result in the damage and rejection of MSCs. As toll like receptors (TLRs) are important in inducing of immune responses, in this study we study the role of TLR7 in mediating the immune status of MSCs isolated from umbilical cord. RESULTS: Our results indicated that TLR7 agonist Imiquimod could increase the proliferation of PBMC isolated from healthy human volunteers and release of lactate dehydrogenase (LDH) in supernatant from PBMC-UCMSCs co-culture system. Flow cytometry and quantitative PCR also confirmed the regulated expression of surface co-stimulatory molecules and pro-inflammatory genes (IL-6, IL-8, IL-12, TGF-β and TNF-α). And the down-regulation expression of stem cell markers also confirmed the loss of stemness of UCMSCs. We also found that the osteo-differentiation ability of UCMSCs was enhanced in the presence of Imiquimod. CONCLUSION: To our knowledge, this is the first report that activation of TLR7 pathway increases the immunogenicity of UCMSCs. Extensive researches have now been conducted to study whether the change of immune status will be help in tumor rejection based on the tumor-tropism of MSCs.

Humans , Adjuvants, Immunologic/pharmacology , Aminoquinolines/pharmacology , Mesenchymal Stem Cells/drug effects , Mesenchymal Stem Cells/immunology , /agonists , Antigens, CD/drug effects , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Flow Cytometry , Gene Expression Regulation/drug effects , /analysis , /analysis , /analysis , L-Lactate Dehydrogenase/drug effects , L-Lactate Dehydrogenase , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Membrane Proteins/drug effects , Osteogenesis/drug effects , Real-Time Polymerase Chain Reaction , Transforming Growth Factor beta/analysis , Tumor Necrosis Factor-alpha/analysis
Braz. j. med. biol. res ; 43(11): 1054-1061, Nov. 2010. ilus, tab
Article in English | LILACS | ID: lil-564126


Hypnophilin and panepoxydone, terpenoids isolated from Lentinus strigosus, have significant inhibitory activity onTrypanosoma cruzi trypanothione reductase (TR). Although they have similar TR inhibitory activity at 10 μg/mL (40.3 μM and 47.6 μM for hypnophilin and panepoxydone, respectively; ~100 percent), hypnophilin has a slightly greater inhibitory activity (~71 percent) on T. cruzi amastigote (AMA) growth in vitro as well as on in vitro phytohemagglutinin (PHA)-induced peripheral blood mononuclear (PBMC) proliferation (~70 percent) compared to panepoxydone (69 percent AMA inhibition and 91 percent PBMC inhibition). Hypnophilin and panepoxydone at 1.25 μg/mL had 67 percent inhibitory activity onLeishmania (Leishmania) amazonensis amastigote-like (AMA-like) growth in vitro. The panepoxydone activity was accompanied by a significant inhibitory effect on PHA-induced PBMC proliferation, suggesting a cytotoxic action. Moreover, incubation of human PBMC with panepoxydone reduced the percentage of CD16+ and CD14+ cells and down-regulated CD19+, CD4+ and CD8+ cells, while hypnophilin did not alter any of the phenotypes analyzed. These data indicate that hypnophilin may be considered to be a prototype for the design of drugs for the chemotherapy of diseases caused by Trypanosomatidae.

Humans , Antiprotozoal Agents/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Leishmania/drug effects , Lentinula/chemistry , Plant Extracts/pharmacology , Sesquiterpenes/pharmacology , Trypanosoma cruzi/drug effects , Antigens, CD/drug effects , Bridged Bicyclo Compounds, Heterocyclic/isolation & purification , Cell Proliferation/drug effects , Drug Design , Leukocytes, Mononuclear/drug effects , Sesquiterpenes/isolation & purification